Factors Likely To Decide Nu Skin’s (NUS) Fate In Q2 Earnings
Nu Skin Enterprises, Inc. NUS is likely to display year-over-year declines in the top and bottom lines when it reports second-quarter 2022 earnings on Aug 4.
Why Earnings Season Could Be Great For Corteva (CTVA)
Investors are always looking for stocks that are poised to beat at earnings season and Corteva, Inc. (NYSE: CTVA), may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
Clorox (CLX) Readies For Q4 Earnings: What’s In The Cards?
The Clorox Company CLX is likely to register top-line growth when it reports fourth-quarter fiscal 2022 earnings on Aug 3. The Zacks Consensus Estimate for quarterly revenues is pegged at $1,856 million, suggesting a rise of around 3% from the prior-year quarter's reported figure.
Looking Into Corteva’s Recent Short Interest
Corteva's (NYSE:CTVA) short percent of float has fallen 25.45% since its last report. The company recently reported that it has 5.89 million shares sold short, which is 0.82% of all regular shares that are available for trading.
Where Corteva Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Corteva (NYSE:CTVA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Analyzing Corteva’s Short Interest
Corteva's (NYSE:CTVA) short percent of float has fallen 18.52% since its last report. The company recently reported that it has 7.92 million shares sold short, which is 1.1% of all regular shares that are available for trading.
Peering Into Corteva’s Recent Short Interest
Corteva's (NYSE:CTVA) short percent of float has risen 9.72% since its last report. The company recently reported that it has 5.73 million shares sold short, which is 0.79% of all regular shares that are available for trading.
Deutsche Bank Maintains Buy on Corteva, Raises Price Target to $72
Deutsche Bank analyst David Begleiter maintains Corteva (NYSE:CTVA) with a Buy and raises the price target from $64 to $72.
What 7 Analyst Ratings Have To Say About Corteva
Within the last quarter, Corteva (NYSE:CTVA) has observed the following analyst ratings: